Compound Summary
Compound Name: | 			Tyrphostin AG 835 | 
Compound CID: | 			5328769 | 
Synonyms: | 			Tyrphostin AG 835 133550-37-5 Tyrphostin B44, (+) enantiomer TYRPHOSTINAG835 Tyrphostin B50 More... | 
Iupac Name: | 			(E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-[(1S)-1-phenylethyl]prop-2-enamide | 
InChI: | 					InChI=1S/C18H16N2O3/c1-12(14-5-3-2-4-6-14)20-18(23)15(11-19)9-13-7-8-16(21)17(22)10-13/h2-10,12,21-22H,1H3,(H,20,23)/b15-9+/t12-/m0/s1 | 
InChIKey: | 				UMGQVUWXNOJOSJ-DGGAMASNSA-N | 
Canonical Smiles: | 		CC(C1=CC=CC=C1)NC(=O)C(=CC2=CC(=C(C=C2)O)O)C#N | 
Isomeric Smiles: | 			C[C@@H](C1=CC=CC=C1)NC(=O)/C(=C/C2=CC(=C(C=C2)O)O)/C#N | 
Molecular Weight: | 		308.3 | 
Molecular Formula: | 			C18H16N2O3 | 
Molecular Weight: | 		308.3 | 
Molecular Formula: | 			C18H16N2O3 | 
Hydrogen Bond Donor Count: | 			3 | 
Hydrogen Bond Acceptor Count: | 			4 | 
Rotatable Bond Count: | 			4 | 
Heavy Atom Count: | 					23 | 
Complexity: | 				488 | 
| Tyrphostin AG 835 | Tyrphostin AG 835 | 
|---|---|
Tyrphostin AG 835 | 			
133550-37-5 | 
Tyrphostin B44, (+) enantiomer | 			
TYRPHOSTINAG835 | 
Tyrphostin B50 | 			
(E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(1S)-1-phenylethylprop-2-enamide | 
MFCD00209855 | 			
(2E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(1S)-1-phenylethylprop-2-enamide | 
Tyrphostin Ag-835 | 			
tyrphostin-AG-835 | 
Tocris-0579 | 			
Tyrphostin deriv. 50 | 
Lopac-T-4443 | 			
Lopac-T-5568 | 
Lopac0_001198 | 			
BDBM4305 | 
CHEMBL261557 | 			
SCHEMBL12856415 | 
Tyrphostin AG 835, >=92% | 			
DTXSID101017645 | 
HMS3263P17 | 			
HMS3266M20 | 
HMS3414G21 | 			
HMS3678G21 | 
ZINC2557951 | 			
Tox21_501198 | 
HSCI1_000020 | 			
(2E)-2-Cyano-3-(3,4-Dihydroxyphenyl)-N-(1S)-1-Phenylethyl-2-Propenamide | 
AKOS024458569 | 			
CCG-205272 | 
LP01198 | 			
SDCCGSBI-0051165.P002 | 
NCGC00016022-01 | 			
NCGC00016022-02 | 
NCGC00024663-01 | 			
NCGC00024663-02 | 
NCGC00024663-03 | 			
NCGC00024663-04 | 
NCGC00261883-01 | 			
AS-73062 | 
EU-0101198 | 			
T3540 | 
T 5568 | 			
SR-01000597624 | 
SR-01000597624-1 | 			
BRD-K17415526-001-02-7 | 
(S)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(1-phenylethyl)acrylamide | 			
(S)-N-(alpha-Methylbenzyl)-3,4-dihydroxybenzylidenecyanoacetamide | 
(S,E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(1-phenylethyl)acrylamide | 			
2-Cyano-3-(3,4-dihydroxyphenyl)-N-(S)-1-phenylethylacrylamide | 
(+)-(S)-N-(alpha-Methylbenzyl)-3,4-dihydroxy-benzylidenecyanoacetamide | 			
(+)-(S)-N-(alpha-Methylbenzyl)-3,4-dihydroxybenzylidenecyanoacetamide | 
(S)-(E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-(1-phenylethyl)-2-propenamide | 			
2-Propenamide,2-cyano-3-(3,4-dihydroxyphenyl)-N-(1S)-1-phenylethyl-,(2E)- | 
(S)-N-(alpha-Methylbenzyl)-3,4-dihydroxybenzylidenecyanoacetamide / (S)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-(1-phenylethyl)acrylamide | 			
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | 1.000000000000000 | NS | N2 | 24134630 | Inactive | 
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point | 
|---|---|---|---|---|
| Caenorhabditis elegans | 1.000000000000000 | 1 | 1 |